The Role of 18F-FDG-PET for Staging and Prognostication

Sponsor
Fondazione Italiana Linfomi ONLUS (Other)
Overall Status
Recruiting
CT.gov ID
NCT04600804
Collaborator
(none)
200
31
26.1
6.5
0.2

Study Details

Study Description

Brief Summary

A retrospective, multicenter, non-interventional, imaging study ancillary to FIL_MCL0208 clinical trial (NCT02354313) in untreated adult patients with mantle cell lymphoma.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is a retrospective, multicenter, non-interventional, imaging study devoted to patients diagnosed with MCL and enrolled in the MCL0208 international randomized, phase III clinical trial (NCT02354313).

    The study is aimed at addressing a number of prognostic issues that still need to be clarified in MCL patients, by taking advantage of the PET performed within the MCL0208 trial and available for the analysis, and the clinical records and molecular data generated in the context of the trial.

    In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after-ASCT (eot-PET), and none of the exams was used in the decisionmaking strategy. All the PETs available will be collected and considered for analysis. The study will not require additional treatment or procedures except those required for the MCL0208 trial. The participation of the patient to the MCL0208 trial is a pre-requisite to be involved in this study.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    The Role of 18F-FDG-PET for Staging and Prognostication in Patients Enrolled in the Fondazione Italiana Linfomi (FIL) MCL0208 Trial
    Actual Study Start Date :
    Oct 30, 2020
    Anticipated Primary Completion Date :
    Sep 1, 2022
    Anticipated Study Completion Date :
    Jan 1, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    All patients registered in the MCL0208 trial

    About 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed. In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after- ASCT (eot-PET). All the PETs available per patient will be collected and considered for analysis, both in the case PET are available at all the 3 time points above listed and in case of availability of PET at 1 or 2 time points only.

    Outcome Measures

    Primary Outcome Measures

    1. Sensitivity (proportion) and agreement (Cohen K) of PET results (performed in different time points) compared to the current standard (TC plus bone marrow biopsy). [24 months]

      To better define the role of PET for the staging of MCL patients at the time of diagnosis, for evaluation of response after induction treatment (pre-ASCT; i-PET) and post ASCT (eot-PET) in comparison to the current standards, namely computed axial tomography (CT) and bone marrow biopsy.

    2. C-index, estimated comparing models adding or not PET parameters to standard prognostic factors in predicting PFS. [24months]

      To build a new prognostic model for PFS, including PET parameters, MIPI-b and biological data (e.g. MRD, GEP and mutational parameters).The achievement of these objectives could help to plan futures studies in order to improve the outcome of MCL patients.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Enrollment of the patient in the MCL0208 clinical trial documented by the signature of the study informed consent;

    • Patient's treatment in one of the centers that participated in the MCL0208 trial and that has joined the MCL0208-PET study as well;

    • Evidence of signed informed consent for the MCL0208-PET study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ematologia Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria Calabria Italy 89124
    2 U.O.Ematologia Ospedale Guglielmo da Saliceto Piacenza Emilia Romagna Italy 29121
    3 Ematologia Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova Reggio Emilia Emilia Romagna Italy 42123
    4 U.O. di Ematologia Ospedale degli Infermi di Rimini Rimini Emilia Romagna Italy 47923
    5 S.O.C. Oncologia Medica A Centro Riferimento Oncologico Aviano Friuli Venezia Giulia Italy 33081
    6 SOC Clinica Ematologica Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) Udine Friuli Venezia Giulia Italy 33100
    7 Ematologia Universitа Cattolica S. Cuore Roma Latium Italy 00168
    8 Ematologia Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l Oncologia Genova Liguria Italy 16132
    9 U.O. Clinica Ematologica Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l Oncologia Genova Liguria Italy 16132
    10 Ematologia Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda Milano Lombardia Italy 20122
    11 SC Ematologia ASST Grande Ospedale Metropolitano Niguarda Milano Lombardia Italy 20162
    12 Ematologia ASST MONZA Ospedale S. Gerardo Monza Lombardia Italy 20900
    13 Div. di Ematologia IRCCS Policlinico S. Matteo di Pavia Pavia Lombardia Italy 27100
    14 U.O. Ematologia Istituto Clinico Humanitas Rozzano Lombardia Italy 20089
    15 Ematologia ASST Spedali Civili di Brescia Brescia Lombardy Italy 25123
    16 S.C. Ematologia A.O. SS. Antonio e Biagio e Cesare Arrigo Alessandria Piedmont Italy 15121
    17 S.C. di Ematologia e Trapianto di Midollo Osseo A.O. S. Croce e Carle Cuneo Piedmont Italy 12100
    18 SCDU Ematologia AOU Maggiore della Caritа di Novara Novara Piedmont Italy 28100
    19 Ematologia Universitaria A.O.U. Citta della Salute e della Scienza di Torino Turin Piedmont Italy 10126
    20 S.C.Ematologia A.O.U. Citta della Salute e della Scienza di Torino Turin Piedmont Italy 10126
    21 Ematologia Ospedale Vito Fazzi Lecce Puglia Italy 73100
    22 U.O.C Ematologia e Trapianto A.O. C. Panico Tricase Puglia Italy 73039
    23 SC Ematologia e CTMO Ospedale Businco Cagliari Sardinia Italy 09121
    24 U.O.C. Ematologia e CTMO P.O. San Francesco Nuoro Sardinia Italy 08100
    25 S.C. Ematologia Azienda Ospedali Riuniti Papardo-Piemonte Messina Sicily Italy 98158
    26 Divisione di Ematologia A.O. Ospedali Riuniti Villa Sofia-Cervello Palermo Sicily Italy 90146
    27 Divisione di Ematologia e T.M.O. - Ospedale Centrale di Bolzano Bolzano Trentino Alto Adige Italy 39100
    28 Unitа funzionale di Ematologia Azienda Ospedaliera Universitaria Careggi Firenze Tuscany Italy 50141
    29 S.C. Oncoematologia A.O. S. Maria di Terni Terni Umbria Italy 05100
    30 S.C di Ematologia Ospedale Ca Foncello Treviso Veneto Italy 31100
    31 U.O. Ematologia AOU Integrata di Verona Verona Veneto Italy 37134

    Sponsors and Collaborators

    • Fondazione Italiana Linfomi ONLUS

    Investigators

    • Principal Investigator: Michael Mian, MD, Ematologia e Centro Trapianto Midollo Osseo, Ospedale di Bolzano, Italy

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fondazione Italiana Linfomi ONLUS
    ClinicalTrials.gov Identifier:
    NCT04600804
    Other Study ID Numbers:
    • FIL_MCL0208-PET
    First Posted:
    Oct 23, 2020
    Last Update Posted:
    Jun 9, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Fondazione Italiana Linfomi ONLUS
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 9, 2022